Company Overview and News

 
UPDATE - Nasdaq Hosted 3rd Nasdaq International Designation Virtual Investor Conference

2018-04-18 globenewswire
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced the conclusion of its 3rd Nasdaq International Designation Virtual Investor Conference on April 4, 2018. Nasdaq welcomed select Nasdaq International Designation Member Companies to present their current state of business to a broad audience including potential investors. The Conference also provided individual and institutional investors an opportunity to engage with CEOs, CFOs, and IROs from a wide range of sectors globally.
Upvote Downvote

 
Alexium International Group chairman buys shares on-market

2017-08-03 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has had 100,000 of its shares purchased by its chairman, Gavin Rezos.
Upvote Downvote

 
Alexium International Group being led by Van Hyning

2017-08-01 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has successfully made the transition that has seen Dirk Van Hyning installed as CEO.
Upvote Downvote

 
Alexium International Group ships record monthly products

2017-06-23 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) is currently closing out what is tracking to be its first month of cash neutrality with increased sales leading to record monthly product shipments.
Upvote Downvote

 
Alexium Organizational Changes support Product Sales focus; Affirmation of Planned Management Succession

2017-05-15 marketwired
PERTH, AUSTRALIA and GREER, SC--(Marketwired - May 15, 2017) - Alexium International Group Limited ("Alexium," "the Company,") (ASX: AJX) (NASDAQ Designation: AXXIY) has affirmed previously announced management succession and highlighted new roles within the Company for several team members as the focus moves to increased commercial product sales across flame retardant (FR) formulations and phase change material (PCM) cooling formulations.
Upvote Downvote

 
Alexium International Group wins U.S. business award

2017-05-09 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has won an award at the 15th annual American Business Awards to be presented during June in New York.
Upvote Downvote

 
UPDATE - Alexium Releases Quarterly Activities Report For The Period Ended 31 March 2017

2017-04-26 marketwired
PERTH, AUSTRALIA and GREER, SC--(Marketwired - Apr 25, 2017) - Alexium International Group Limited ("Alexium," "the Company") (ASX: AJX) (NASDAQ Designation: AXXIY) today announced the release of the Quarterly Activities Report for the Period Ended 31 March 2017. The Report is available to view online by clicking here.
Upvote Downvote

 
Benwel, Inc. to Market Auto Racing Safety Fire Retardant (FR) Garments Treated With Alexiflam(TM) and Alexicool(TM)

2017-04-12 marketwired
Alexium International Group Limited ("Alexium," "the Company") (ASX: AJX) (NASDAQ Designation: AXXIY) announced today that it has formally partnered with Benwel, Inc., a South Carolina-based uniform developer, to introduce an FR undergarment for the auto racing industry treated with both Alexiflam™ and Alexicool™ technology.
Upvote Downvote

 
Alexium International Group partners with U.S. company

2017-04-12 proactiveinvestors.com.au
Alexium will work with Benwell to introduce a fire retardant undergarment for the auto racing industry treated with both Alexiflam™ and Alexicool™ technology.
Upvote Downvote

 
Alexium Appoints Former US Congresswoman Karen Thurman to Board of Directors

2017-03-06 marketwired
PERTH, AUSTRALIA and GREER, SC--(Marketwired - Mar 6, 2017) - Alexium International Group Limited ("Alexium," "the Company") (ASX: AJX) (OTC- Nasdaq Int'l: AXXIY) is pleased to welcome former United States Congresswoman Karen Thurman to its Board of Directors as a Non-Executive Board Member. 
Upvote Downvote

 
Alexium International Group welcomes former U.S. congresswoman

2017-03-02 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has welcomed former U.S. congresswoman Karen Thurman to its board as a non-executive director.
Upvote Downvote

 
Alexium International Group promotes Dirk Van Hyning to CEO

2017-02-28 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has promoted Dirk Van Hyning to the position of chief executive officer, effective from June 30th, 2017.
Upvote Downvote

 
Alexium International Group admitted to NASDAQ International Designation

2017-01-16 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has been admitted to NASDAQ International Designation, which will increase visibility for its current traded securities in the U.S.
Upvote Downvote

 
Agreement With Pegasus Home Fashions, Major Pillow Producer for Six US Top Tier Retailers

2017-01-04 marketwired
Initial Agreement Representing US$10M+ in Ongoing Annual Revenue to Alexium will Enable Pegasus' New Cool-Touch Pillow Sales to Mass Brand Retailers across North America
Upvote Downvote

 
Alexium International Group boosts revenue through Mass Brand supply

2017-01-04 proactiveinvestors.com.au
Alexium International Group (ASX:AJX) has signed an initial agreement to supply its Alexicool™ chemistry representing US$10+ million in annual sales.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...